These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 3127847

  • 1. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M, Lyon RA, Glennon RA.
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [Abstract] [Full Text] [Related]

  • 2. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
    Titeler M, Lyon RA, Davis KH, Glennon RA.
    Biochem Pharmacol; 1987 Oct 01; 36(19):3265-71. PubMed ID: 3663239
    [Abstract] [Full Text] [Related]

  • 3. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.
    Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M.
    Psychopharmacology (Berl); 1989 Oct 01; 98(4):495-9. PubMed ID: 2505289
    [Abstract] [Full Text] [Related]

  • 4. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors.
    Buckholtz NS, Zhou DF, Freedman DX.
    Life Sci; 1988 Oct 01; 42(24):2439-45. PubMed ID: 3374263
    [Abstract] [Full Text] [Related]

  • 5. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA, Peroutka SJ.
    J Pharmacol Exp Ther; 1988 Dec 01; 247(3):918-25. PubMed ID: 3204523
    [Abstract] [Full Text] [Related]

  • 6. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
    Glennon RA, Titeler M, Lyon RA.
    Pharmacol Biochem Behav; 1988 Jul 01; 30(3):597-601. PubMed ID: 3211969
    [Abstract] [Full Text] [Related]

  • 7. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA, Peroutka SJ.
    Psychopharmacology (Berl); 1989 Jul 01; 97(1):118-22. PubMed ID: 2540505
    [Abstract] [Full Text] [Related]

  • 8. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M, Herrick K, Lyon RA, McKenney JD, Glennon RA.
    Eur J Pharmacol; 1985 Oct 29; 117(1):145-6. PubMed ID: 4085543
    [No Abstract] [Full Text] [Related]

  • 9. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex.
    Arvanov VL, Liang X, Russo A, Wang RY.
    Eur J Neurosci; 1999 Sep 29; 11(9):3064-72. PubMed ID: 10510170
    [Abstract] [Full Text] [Related]

  • 10. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.
    Glennon RA, Titeler M, McKenney JD.
    Life Sci; 1984 Dec 17; 35(25):2505-11. PubMed ID: 6513725
    [Abstract] [Full Text] [Related]

  • 11. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
    Lyon RA, Davis KH, Titeler M.
    Mol Pharmacol; 1987 Feb 17; 31(2):194-9. PubMed ID: 3543649
    [Abstract] [Full Text] [Related]

  • 12. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
    Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP.
    J Pharmacol Exp Ther; 2007 Jun 17; 321(3):1054-61. PubMed ID: 17337633
    [Abstract] [Full Text] [Related]

  • 13. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
    Buckholtz NS, Zhou DF, Freedman DX, Potter WZ.
    Neuropsychopharmacology; 1990 Apr 17; 3(2):137-48. PubMed ID: 1969270
    [Abstract] [Full Text] [Related]

  • 14. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ, Aghajanian GK.
    J Pharmacol Exp Ther; 1996 Sep 17; 278(3):1373-82. PubMed ID: 8819525
    [Abstract] [Full Text] [Related]

  • 15. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E, Burris KD, Knoth K.
    J Pharmacol Exp Ther; 1988 Sep 17; 246(3):924-8. PubMed ID: 2843634
    [Abstract] [Full Text] [Related]

  • 16. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin.
    Hoyer D, Engel G, Kalkman HO.
    Eur J Pharmacol; 1985 Nov 26; 118(1-2):13-23. PubMed ID: 2935410
    [Abstract] [Full Text] [Related]

  • 17. Serotonin excitation of facial motoneurons: receptor subtype characterization.
    Rasmussen K, Aghajanian GK.
    Synapse; 1990 Nov 26; 5(4):324-32. PubMed ID: 2360199
    [Abstract] [Full Text] [Related]

  • 18. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
    Heller WA, Baraban JM.
    Eur J Pharmacol; 1987 Jun 12; 138(1):115-7. PubMed ID: 3622603
    [Abstract] [Full Text] [Related]

  • 19. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    Peroutka SJ, Hamik A, Harrington MA, Hoffman AJ, Mathis CA, Pierce PA, Wang SS.
    Mol Pharmacol; 1988 Oct 12; 34(4):537-42. PubMed ID: 3173334
    [Abstract] [Full Text] [Related]

  • 20. Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites.
    Buchborn T, Schröder H, Dieterich DC, Grecksch G, Höllt V.
    Behav Brain Res; 2015 Mar 15; 281():62-8. PubMed ID: 25513973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.